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Abstract The proton-translocating NADH-quinone oxidore-
ductase in mitochondria (complex I) and bacteria (NDH-1)
was shown to be inhibited by amiloride derivatives that are
known as speci¢c inhibitors for Na+/H+ exchangers. In bovine
submitochondrial particles, the e¡ective concentrations were
about the same as those for the Na+/H+ exchangers, whereas
in bacterial membranes the inhibitory potencies were lower.
These results together with our earlier observation that the ami-
loride analogues prevent labeling of the ND5 subunit of complex
I with a fenpyroximate analogue suggest the involvement of
ND5 in H+ (Na+) translocation and no direct involvement of
electron carriers in H+ (Na+) translocation.
* 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
The proton-translocating NADH-quinone oxidoreductase
in mitochondria and bacteria is a component of the oxidative
phosphorylation system and catalyzes electron transport from
NADH to quinone that is coupled to proton translocation [1^
3]. The mitochondrial enzyme, also known as complex I, is
located in the inner mitochondrial membrane and composed
of 46 di¡erent subunits [4]. The bacterial enzyme, NDH-1, is
in the cytoplasmic membrane and contains 14 subunits [5].
Despite the di¡erence in the size, complex I and NDH-1 share
many properties in terms of structure and function. Both en-
zymes consist of two major domains [6^8]. One is a peripheral
domain that protrudes into the mitochondrial matrix (or the
cytoplasm) and bears prosthetic groups such as FMN (£avin
mononucleotide) and iron^sulfur centers. The other is a mem-
brane domain bearing hydrophobic subunits. Recent studies
suggest that the two domains have distinct functions, the pe-
ripheral domain is a cofactor-binding segment and the mem-
brane domain is a proton pumping unit [3,9,10]. It has also
been demonstrated that the NDH-1 in Escherichia coli and
Klebsiella pneumoniae can pump Naþ [11,12]. In fact, some
of the subunits in the membrane domain were found to have
high sequence similarity to certain Naþ/Hþ antiporters which
are considered to house no cofactors [13,14].
We have recently shown that, in bovine complex I, one of
the membrane domain subunits, ND5, is labeled by a photo-
a⁄nity analogue of a potent inhibitor of complex I, fenpyr-
oximate (TDF), and that this labeling is almost completely
prevented by addition of amiloride derivative such as 5-(N-
methyl-N-isobutyl)amiloride (MIA) and 5-(N-ethyl-N-isopro-
pyl) amiloride (EIPA) [15]. This is interesting because the
amiloride derivatives employed have been known to be spe-
ci¢c inhibitors for Naþ/Hþ antiporters [16^18]. In this paper,
we report the inhibitory e¡ect of amiloride derivatives on the
activities of complex I/NDH-1 from di¡erent sources.
2. Materials and methods
Bovine heart mitochondria were generously provided by Dr. C.-A.
Yu (Oklahoma State University, OK, USA). Submitochondrial par-
ticles (SMP) were prepared as described in [19]. EIPA, MIA and
benzamil were from Sigma. All other chemicals were of the highest
grade.
An E. coli mutant lacking NDH-2 was constructed as follows. The
ndh gene which encodes NDH-2 was cloned by polymerase chain
reaction (PCR) together with a V900 bp DNA segment upstream
and a V400 bp DNA segment downstream with genomic DNA pu-
ri¢ed from E. coli DH5K according to [20]. We used a sense primer,
CACGAGAAAGGGATCCAATTGCAGTTTATTGACCCGG (un-
derlined bases were altered from E. coli DNA and the italicized bases
represent the restriction sequence) in order to generate a BamHI site
and an anti-sense primer, CCTGCACCGGTCGACGATGGGT-
CACTGTGACG containing the naturally occurred SalI site. The
spectinomycin cassette encoding gene from the Staphylococcus aureus
transposon Tn554 [21] was cloned by using the sense primer,
CGGGGTCCCATGGTCAGTGGAACGAAAACTCACG and the
anti-sense primer, AAGGACCATGGTCTTTCTATTTTCAATAGT-
TAC, both containing a NcoI restriction site represented by italicized
bases. The DNA fragment containing the ndh gene together with the
spectinomycin cassette was assembled in pPCR-Script (Stratagene)
by using the NcoI site naturally occurred in the middle of the ndh
gene and ¢nally the 2.7 kb BamHI^NcoI^SalI fragment was trans-
ferred into pKO3, which was kindly provided by Dr. G.M. Church
(Harvard Medical School, MA, USA), a gene replacement vector that
contains a temperature-sensitive origin of replication and markers for
positive and negative selection for chromosomal integration and ex-
cision. The resulting construct was designated pKO3(ndh-spc). The
E. coli strain MC4100 was transformed with the pKO3(ndh-spc) plas-
mid, and homologous recombination was carried out as described in
[22]. The disruption of the ndh gene was veri¢ed by PCR and DNA
sequencing.
Cholate-treated Paracoccus denitri¢cans membranes, E. coli and
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Bacillus subtilis membranes were prepared according to the method
reported previously [7].
SMP (10^30 Wg ml31) or bacterial membranes (20^140 Wg ml31)
were incubated in the presence of an amiloride derivative for 5 min
at 30‡C in a bu¡er containing 50 mM sodium phosphate (pH 7.4) and
1 mM EDTA. Activities were measured at 30‡C in the same bu¡er as
a decrease of absorbance at 340 nm (O340 = 6.22 mM31 cm31) with
150 WM NADH (NADH oxidase) or, with 150 WM NADH and
100 WM ubiquinone-1 (Q1) in the presence of 2 mM KCN and
0.2 WM antimycin A (NADH-quinone reductase). The NADH-
K3Fe(CN)6 reductase activity was determined from an absorbance
decrease at 420 nm (O420 = 1.0 mM31 cm31) with 150 WM NADH,
1 mM K3Fe(CN)6, 2 mM KCN and 0.2 WM antimycin A.
Protein concentration was estimated by the method of Lowry et al.
[23]. Any variations from the procedures and details are described in
the ¢gure legends.
3. Results
As mentioned above, the ND5 subunit of complex I in
bovine heart SMP can be labeled by a photoa⁄nity analogue
of TDF and the labeling was almost completely prevented by
the presence of amiloride analogues as well as other complex I
inhibitors [15]. Since amiloride derivatives have been known
as speci¢c inhibitors for Naþ-related transporters such as
Naþ/Hþ exchangers and Naþ/Kþ ATPase [16,18,24], we in-
vestigated the e¡ect of these inhibitors on complex I activities.
Incubation of SMP with an amiloride derivative, MIA, re-
sulted in inhibition of the NADH oxidase activity as shown
in Fig. 1. The concentration of half maximal inhibition (IC50)
for MIA was approximately 5 WM. The inhibition pro¢le re-
mained the same regardless of the SMP concentration used.
Addition of NaCl at 50 mM did not a¡ect the degree of in-
hibition. Two other amiloride derivatives tested, benzamil and
EIPA, both inhibited the NADH oxidation in a similar fash-
ion. Benzamil and EIPA were slightly less e¡ective than MIA
both with an IC50 value of 17 WM (Fig. 1 and Table 1). In the
case of the Naþ/Hþ exchangers, inhibitory concentrations re-
ported for MIA, benzamil and EIPA vary from low (less than
micromolar) to high (hundreds of micromolar) depending on
the types and sources [17,25,26]. The e¡ective concentrations
of the amiloride inhibition of complex I are well within the
reported range for inhibition of the Naþ/Hþ exchangers. The
greater potency of MIA over EIPA agrees with our previous
result of suppression of the TDF labeling of the ND5 subunit
in which MIA was shown to be more e¡ective than EIPA [15].
The amiloride derivatives also inhibited NADH-quinone re-
ductase activity but did not a¡ect NADH-K3Fe(CN)6 reduc-
tase activity or succinate oxidase activity in bovine SMP at up
to 100 WM (data not shown). Therefore, it is likely that the
inhibition site is located in the membrane domain of complex
I, consistent with the result of suppression of ND5 labeling
with TDF [15].
Complex I inhibitors that are known to act downstream of
iron^sulfur centers may be grouped into two types on the
basis of kinetic behavior against quinone. One group of in-
hibitors including piericidin A displays competitive inhibition
with respect to quinone and most likely share a common bind-
ing site with quinone. The other group shows non-competitive
inhibition and their binding site may not overlap with the
quinone binding site. We have examined the competition
mode of MIA for NADH-Q1 reductase activity in bovine
SMP. As shown in Fig. 2, MIA worked as a non-competitive
inhibitor against quinone. These results may indicate that the
amiloride inhibitors do not a¡ect the apparent Km values for
quinone, suggesting that they do not bind to the quinone-
biding site but act somewhere between quinone and center
N2 (of the highest Em value of electron carriers in complex
I). Interestingly, Gong et al. [27] reported in a recent paper
that binding of a photoa⁄nity analogue of quinone to the
E. coli NDH-1 was not in£uenced by addition of complex I
inhibitors.
Amiloride and its derivatives are known to inhibit a wide
variety of Naþ/Hþ exchangers from di¡erent sources such as
bacteria and yeast in addition to mammals. The inhibitory
action and potencies di¡er depending on the species. For ex-
ample, amiloride is a potent inhibitor for an Naþ/Hþ anti-
porter (NhaA) in the marine bacterium Vibrio parahaemolyti-
cus but displays no signi¢cant inhibitory e¡ect on the E. coli
Fig. 1. Inhibition of NADH oxidase activity by amiloride derivatives in bovine SMP. SMP were incubated with the indicated concentrations of
MIA (left), benzamil (center) or EIPA (right) for 5 min at 30‡C and then assayed for NADH oxidase activity as detailed in Section 2. The
SMP concentration was either 0.22 mg ml31 (circles) or 0.11 mg ml31 (triangles).
Table 1
IC50 values of amiloride analogues for NADH oxidase activity
Membrane IC50 for NADH oxidase activity (WM)
MIA Benzamil EIPA
Bovine SMPa 5 17 17
P. denitri¢cans 20 42 63
E. coli (NDH-1)b 45 45 s 100
E. coli (NDH-2)c E100d E100d no inhibition
B. subtilis (NDH-2) V100 V100 E100d
aThere were slight variations in the IC50 values among preparations.
However, bovine SMP reproducibly showed lower values than bac-
terial membranes.
bAn E. coli mutant lacking NDH-2 was used.
cActivity was measured with wild-type E. coli under the conditions
in which s 95% of the activity of NDH-1 is inhibited in the pres-
ence of 2.5 WM piericidin A.
dInhibition was 30% or less at 100 WM of the inhibitor.
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NhaA [28,29]. Steuber’s group demonstrated that E. coli and
K. pneumoniae NDH-1 can pump Naþ [11,30]. In addition, it
has been reported that the expressed E. coli NuoL (ND5
homologue) subunit can transport Naþ and this Naþ trans-
port is suppressed by EIPA [31]. Therefore, it is of interest to
see if the amiloride derivatives inhibit energy-transducing ac-
tivity of bacterial NDH-1. We have examined their e¡ect on
the NADH oxidase activity of several bacterial membranes
(Table 1). All compounds inhibited the bacterial membranes
but with di¡erent potencies. In the case of P. denitri¢cans
membranes, MIA inhibited the NADH oxidase activity with
an IC50 of 20 WM and displayed s 90% inhibition at 50 WM.
Succinate oxidation was not a¡ected by MIA at least up to 40
WM (data not shown). The IC50 values of benzamil and EIPA
for P. denitri¢cans membranes were also three to four times
higher than those for bovine SMP. In contrast to P. denitri-
¢cans which contains the NDH-1 as the sole NADH dehy-
drogenase [32], E. coli has rotenone-insensitive NADH dehy-
drogenase (NDH-2) in addition to NDH-1. To measure the
activity of NDH-1 in E. coli, we constructed a mutant lacking
NDH-2 and used its membrane preparations. When compared
to P. denitri¢cans, the IC50 value for benzamil in the E. coli
NDH-1 was about the same but those for MIA and EIPA
were twice as high. Also shown in Table 1 is the e¡ect of
amiloride derivatives on the NDH-2 enzyme. The inhibition
of NDH-2 was assessed in two ways. One is to use the mem-
brane from wild-type E. coli which has both NDH-1 and
NDH-2. The activity of NDH-2 can be measured by addition
of piericidin A which selectively inhibits NDH-1. Another
source of NDH-2 is B. subtilis because it does not harbor
NDH-1. The NDH-2 enzyme from either bacterium was
much less sensitive to all compounds tested. This was most
notable with EIPA which, at 100 WM, did not inhibit the
E. coli NDH-2 and exhibited only 30% inhibition with B. sub-
tilis. The di¡erence in the inhibitory potencies between NDH-
1 and NDH-2 and the species speci¢city observed for amilor-
ide analogues are similar to those reported for common com-
plex I inhibitors. P. denitri¢cans NDH-1 tends to show inhib-
itor sensitivities that are close to those of mitochondrial
complex I whereas E. coli NDH-1 is in general signi¢cantly
less sensitive to complex I inhibitors [33^35]. It should also be
noted that complex I inhibitors such as rotenone and pierici-
din A partially inhibit NDH-2 but at much higher concentra-
tions [33].
4. Discussion
The mechanism of energy coupling of complex I/NDH-1 is
still speculative. Two types of coupling mechanism have been
proposed [3]. One is direct coupling in which electron carriers
such as quinones are involved in Hþ translocation and the
other is indirect coupling which assumes energy transduction
driven through dynamic conformation changes of the enzyme.
Most recent reports on this subject seem to be in favor of the
indirect coupling mechanism. First, complex I/NDH-1 con-
sists of two distinct domains and all prosthetic groups are
present in the peripheral domain and none is found in the
membrane domain where the Hþ translocation takes place.
Second, it was recently demonstrated that complex I/NDH-1
from E. coli and K. pneumoniae are capable of pumping Naþ
[11,12]; the observation that does not reconcile with the direct
coupling mechanism. In fact, high sequence similarity has
been reported between the ND5 subunit of complex I and
the MnhA subunit of Naþ/Hþ antiporters from various bac-
terial sources [13,14]. If Hþ pumping and Naþ pumping share
a common mechanism, it is highly likely that the ND5 subunit
constitutes a key member in the Naþ/Hþ translocation ma-
chinery. In agreement with this notion, our earlier results of
the TDF labeling of the ND5 subunit indicated that this sub-
unit is part of the proposed inhibitor-binding pocket of com-
plex I that encompasses several subunits [15,36]. Furthermore,
we showed that TDF binding to the ND5 subunit was sup-
pressed by amiloride analogues and that the amiloride deriv-
atives indeed inhibit energy-coupled activities of complex I
and e¡ective concentrations are similar to those for the
Naþ/Hþ exchangers. The precise location of the amiloride
binding site is still not clear. Kinetic data suggest that it is
not the same as the quinone binding site [27]. Recently, Steu-
ber reported that the truncated NuoL (ND5) subunit of E.
coli NDH-1 reconstituted in proteoliposomes can transport
Naþ [31]. Interestingly, this Naþ uptake was diminished by
EIPA. This observation is in perfect agreement with our re-
sults that amiloride analogues, including EIPA, inhibit
NADH oxidase activity of the E. coli NDH-1. Taken all avail-
able data together, we can envision that complex I/NDH-1
may pump Hþ (Naþ) by conformational change which is in-
hibited by amiloride derivatives and that the ND5 subunit
plays an important role in Hþ (Naþ) translocation function
of complex I/NDH-1.
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